Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Relay Therapeutics Inc.

    NASDAQ: RLAY · Real-Time Price · USD
    3.36
    0.12 (3.70%)
    At close: Jun 06, 2025, 9:58 AM

    Relay Therapeutics Statistics

    Share Statistics

    Relay Therapeutics has 171.44M shares outstanding. The number of shares has increased by 27.71% in one year.

    Shares Outstanding

    n/a
    		 171.44M

    Shares Change (YoY)

    n/a
    		 27.71%

    Shares Change (QoQ)

    n/a
    		 1.28%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 96

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    The latest short interest is 23.16M, so 13.51% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 23.16M

    Short % of Shares Out

    n/a
    		 13.51%

    Short % of Float

    n/a
    		 16.41%

    Short Ratio (days to cover)

    n/a
    		 8.14

    Valuation Ratios

    The PE ratio is -1.74 and the forward PE ratio is -1.76. Relay Therapeutics's PEG ratio is 0.11.

    PE Ratio

    n/a
    		 -1.74

    Forward PE

    n/a
    		 -1.76

    PS Ratio

    n/a
    		 58.82

    Forward PS

    n/a
    		 3.2

    PB Ratio

    n/a
    		 0.76

    P/FCF Ratio

    n/a
    		 -2.34

    PEG Ratio

    n/a
    		 0.11
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Relay Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 15.95, with a Debt / Equity ratio of 0.06.

    Current Ratio

    n/a
    		 15.95

    Quick Ratio

    n/a
    		 15.95

    Debt / Equity

    n/a
    		 0.06

    Debt / EBITDA

    n/a
    		 -0.13

    Debt / FCF

    n/a
    		 -0.19

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $38,637.07

    Profits Per Employee

    n/a
    		 $-1,303,891.89

    Employee Count

    n/a
    		 259

    Asset Turnover

    n/a
    		 0.01

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -55.3% in the last 52 weeks. The beta is 1.59, so Relay Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.59

    52-Week Price Change

    n/a
    		 -55.3%

    50-Day Moving Average

    n/a
    		 2.85

    200-Day Moving Average

    n/a
    		 4.68

    Relative Strength Index (RSI)

    n/a
    		 58.49

    Average Volume (20 Days)

    n/a
    		 2,478,923

    Income Statement

    In the last 12 months, Relay Therapeutics had revenue of 10.01M and earned -337.71M in profits. Earnings per share was -2.36.

    Revenue

    n/a
    		 10.01M

    Gross Profit

    n/a
    		 4.54M

    Operating Income

    n/a
    		 -372.47M

    Net Income

    n/a
    		 -337.71M

    EBITDA

    n/a
    		 -372.47M

    EBIT

    n/a
    		 -385.67M

    Earnings Per Share (EPS)

    n/a
    		 -2.36
    Full Income Statement

    Balance Sheet

    The company has 124.29M in cash and 48.5M in debt, giving a net cash position of 75.78M.

    Cash & Cash Equivalents

    n/a
    		 124.29M

    Total Debt

    n/a
    		 48.5M

    Net Cash

    n/a
    		 75.78M

    Retained Earnings

    n/a
    		 -1.74B

    Total Assets

    n/a
    		 799.36M

    Working Capital

    n/a
    		 702.61M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -249.11M and capital expenditures -2.02M, giving a free cash flow of -251.13M.

    Operating Cash Flow

    n/a
    		 -249.11M

    Capital Expenditures

    n/a
    		 -2.02M

    Free Cash Flow

    n/a
    		 -251.13M

    FCF Per Share

    n/a
    		 -1.76
    Full Cash Flow Statement

    Margins

    Gross margin is 45.4%, with operating and profit margins of -3722.07% and -3374.72%.

    Gross Margin

    n/a
    		 45.4%

    Operating Margin

    n/a
    		 -3722.07%

    Pretax Margin

    n/a
    		 -3374.72%

    Profit Margin

    n/a
    		 -3374.72%

    EBITDA Margin

    n/a
    		 -3722.07%

    EBIT Margin

    n/a
    		 -3722.07%

    FCF Margin

    n/a
    		 -2509.49%

    Dividends & Yields

    RLAY does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for RLAY is $18, which is 453.8% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $18

    Price Target Difference

    n/a
    		 453.8%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 11
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 0.38

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist